Utah is currently home to 1202 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219
Recruiting
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Advanced Solid Tumor
Register for Updates
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653
Recruiting
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to en... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Endometrial Cancer
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)
NCT06051721
Recruiting
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/08/2024
Locations: Cedar Clinical Research, Murray, Utah
Conditions: Generalized Anxiety Disorder
Register for Updates
PCMS Task After Moderate-to-severe Stroke
NCT05736653
Recruiting
Researchers at the University of Pittsburgh are conducting a research study to see how combining brain, nerve, and hand stimulation affect hand movement after stroke. The primary purpose of this study is to examine changes in the connection between the brain and the weak hand muscles after the combined brain, nerve, and hand stimulation. The primary hypothesis is that the combined brain, nerve, and hand stimulation will increase the the connection between the brain and the weak hand muscles. The... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/08/2024
Locations: Neural Plasticity Rehabilitation and Movement Dynamics Lab, Salt Lake City, Utah
Conditions: Stroke
Register for Updates
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
ALL
Ages:
1 day and above
Trial Updated:
10/07/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
ALL
Ages:
All
Trial Updated:
10/04/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Melanoma, Herpetic Infection
Register for Updates
Childhood Cancer Predisposition Study (CCPS)
NCT04511806
Recruiting
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contri... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/03/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Pediatric Cancer
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Salt Lake City, Utah
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
Long-term COVID and Rehabilitation
NCT05373043
Recruiting
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/02/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Long-COVID
Register for Updates
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
NCT02848274
Recruiting
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma
Register for Updates
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501
Recruiting
This single-cohort, prospective case series is designed to evaluate and characterize the use of Axoguard HA+ Nerve Protector™ to protect the ulnar nerve in a first revision cubital tunnel decompression procedure. Data on the primary cubital tunnel syndrome decompression, first revision decompression utilizing Axoguard HA+ Nerve Protector, participant-reported pain, motor and sensory functional outcomes, quality of life (QoL) outcomes, and recurrence/revision will be collected. This case series w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Register for Updates